Recent Updates — SGMOQ

Sangamo Therapeutics completed the sale of substantially all assets related to its ST-920 gene therapy candidate for Fabry disease to PTC Therapeutics on September 17, 2026. The transaction involves $111 million in upfront cash and up to $100 million in contingent milestone payments, plus assumption of specified liabilities. This sale follows Sangamo's Chapter 11 bankruptcy filing in June 2026 and a court-supervised auction process that selected PTC as the successful bidder on August 10, 2026. Concurrently, Nasdaq filed Form 25 to delist Sangamo's common stock, effective September 27, 2026, following the denial of its listing appeal in July 2026. The company operates in the biotechnology industry, focusing on gene therapy development.

Sangamo Therapeutics, Inc. completed the sale of substantially all of its assets, including its AAV capsid engineering platform (STAC-BBB), zinc finger protein technology, Modular Integrase genome editing platform, and prion disease program, to Eli Lilly and Company for $50 million in cash plus assumption of specified liabilities. The transaction closed on September 4, 2026, following the company's Chapter 11 bankruptcy filing on June 23, 2026. During the July reporting period, the company incurred $18 million in replacement debtor-in-possession financing obligations and reported a net loss of approximately $11.2 million with ending cash balances of roughly $16.9 million. Sangamo Therapeutics operates in the biotechnology industry, focusing on gene editing and therapeutic development.